<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28246207</article-id><article-id pub-id-type="pmc">5344646</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2016-0479</article-id><article-id pub-id-type="publisher-id">ONCO12049</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>31</subject><subject>7</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>A Phase II, Randomized, Double&#x02010;Blind, Placebo&#x02010;Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second&#x02010;Line Treatment of Metastatic <italic>KRAS</italic> Mutant Colorectal Adenocarcinoma</article-title></title-group><contrib-group><contrib id="onco12049-cr-0001" contrib-type="author" corresp="yes"><name><surname>Hecht</surname><given-names>J. Randolph</given-names></name><address><email>jrhecht@mednet.ucla.edu</email></address><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="onco12049-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12049-cr-0002" contrib-type="author"><name><surname>Benson</surname><given-names>Al B.</given-names><suffix>III</suffix></name><xref ref-type="aff" rid="onco12049-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12049-cr-0003" contrib-type="author"><name><surname>Vyushkov</surname><given-names>Dmitry</given-names></name><xref ref-type="aff" rid="onco12049-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12049-cr-0004" contrib-type="author"><name><surname>Yang</surname><given-names>Yingsi</given-names></name><xref ref-type="aff" rid="onco12049-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12049-cr-0005" contrib-type="author"><name><surname>Bendell</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="onco12049-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12049-cr-0006" contrib-type="author"><name><surname>Verma</surname><given-names>Udit</given-names></name><xref ref-type="aff" rid="onco12049-aff-0006"><sup>f</sup></xref></contrib><aff id="onco12049-aff-0001"><label><sup>a</sup></label><institution>David Geffen School of Medicine at the University of California</institution>, <city>Los Angeles</city>, <state>California</state>, <country country="US">USA</country>
</aff><aff id="onco12049-aff-0002"><label><sup>b</sup></label><institution>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</institution>, <city>Chicago</city>, <state>Illinois</state>, <country country="US">USA</country>
</aff><aff id="onco12049-aff-0003"><label><sup>c</sup></label><institution>Budgetary Healthcare Institution of Omsk Region, Clinical Oncologic Dispensary</institution>, <city>Omsk</city>, <country country="RU">Russia</country>
</aff><aff id="onco12049-aff-0004"><label><sup>d</sup></label><institution>Gilead Sciences, Inc.</institution>, <city>Foster City</city>, <state>California</state>, <country country="US">USA</country>
</aff><aff id="onco12049-aff-0005"><label><sup>e</sup></label><institution>Sarah Cannon Research Institute/Tennessee Oncology</institution>, <city>Nashville</city>, <state>Tennessee</state>, <country country="US">USA</country>
</aff><aff id="onco12049-aff-0006"><label><sup>f</sup></label><institution>The University of Texas Southwestern Medical Center</institution>, <city>Dallas</city>, <state>Texas</state>, <country country="US">USA</country>
</aff></contrib-group><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: J. Randolph Hecht, M.D., David Geffen School of Medicine at the University of California, Los Angeles, California 90404, USA. Telephone: 310&#x02010;592&#x02010;5923; e&#x02010;mail: <email>jrhecht@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>2</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>22</volume><issue>3</issue><issue-id pub-id-type="doi">10.1002/onco.v22.3</issue-id><fpage>243</fpage><lpage>e23</lpage><history><date date-type="received"><day>13</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement content-type="article-copyright">&#x000a9; AlphaMed Press; the data published online to support this summary is the property of the authors.</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="onco12049.pdf"/><abstract><title>Abstract</title><sec id="onco12049-sec-0001"><title>Lessons Learned.</title><p>
<list list-type="bullet" id="onco12049-list-0001"><list-item id="onco12049-li-1200"><p>The safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group.</p></list-item><list-item id="onco12049-li-1201"><p>The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients with metastatic <italic>KRAS</italic> mutant colorectal carcinoma.</p></list-item></list></p></sec><sec id="onco12049-sec-0002"><title>Background.</title><p>Simtuzumab, a humanized IgG4 monoclonal antibody to lysyl oxidase&#x02010;like 2 (LOXL2), blocks desmoplastic reaction in colorectal carcinoma (CRC) cells in vitro.</p></sec><sec id="onco12049-sec-0003"><title>Methods.</title><p>Patients with metastatic Kirsten rat sarcoma viral oncogene homolog (<italic>KRAS</italic>) mutant CRC were randomized to receive second&#x02010;line 5&#x02010;fluorouracil, leucovorin, and irinotecan (FOLFIRI) with either 200 or 700 mg simtuzumab or placebo every 2 weeks in cycles of 28 days. Progression&#x02010;free survival (PFS), overall survival (OS), objective response rate (ORR), and safety were assessed.</p></sec><sec id="onco12049-sec-0004"><title>Results.</title><p>In total, 249 patients were randomized and treated with FOLFIRI/simtuzumab 700 mg (<italic>n</italic>&#x02009;=&#x02009;84), FOLFIRI/simtuzumab 200 mg (<italic>n</italic>&#x02009;=&#x02009;85), and FOLFIRI/placebo (<italic>n</italic>&#x02009;=&#x02009;80). After a median follow&#x02010;up of 5.1, 3.8, and 5.5 months, respectively, median PFS for each of the respective treatment groups was 5.5 months (adjusted HR [95% CI], <italic>p</italic> value versus placebo; 1.32 [0.92, 1.89]; <italic>p</italic>&#x02009;=&#x02009;.10), 5.4 months (1.45 [1.01, 2.06]; <italic>p</italic>&#x02009;=&#x02009;.04), and 5.8 months. Median OS was 11.4 months (1.23 [0.80, 1.91]; <italic>p</italic>&#x02009;=&#x02009;.25), 10.5 months (1.50 [0.98, 2.30]; <italic>p</italic>&#x02009;=&#x02009;.06), and 16.3 months, respectively. ORR was 11.9%, 5.9%, and 10%, respectively. Simtuzumab was tolerable in metastatic <italic>KRAS</italic> mutant CRC patients.</p></sec><sec id="onco12049-sec-0005"><title>Conclusion.</title><p>The addition of simtuzumab to FOLFIRI did not improve clinical outcomes in patients with metastatic <italic>KRAS</italic> mutant CRC.</p></sec></abstract><trans-abstract xml:lang="zh" abstract-type="main"><p xml:lang="zh">&#x07ecf;&#x09a8c;&#x0603b;&#x07ed3;</p><p xml:lang="zh">&#x02022; FOLFIRI+Simtuzumab&#x07ec4;&#x060a3;&#x08005;&#x07684;&#x05b89;&#x05168;&#x06027;&#x07279;&#x05f81;&#x04e0e;FOLFIRI+&#x05b89;&#x06170;&#x05242;&#x07ec4;&#x06ca1;&#x06709;&#x05dee;&#x05f02;&#x03002;</p><p xml:lang="zh">&#x02022; Simtuzumab&#x08054;&#x05408;FOLFIRI&#x05316;&#x07597;&#x0672a;&#x06539;&#x05584;&#x08f6c;&#x079fb;&#x06027;<italic>KRAS</italic>&#x07a81;&#x053d8;&#x07ed3;&#x076f4;&#x080a0;&#x0764c;&#x060a3;&#x08005;&#x07684;&#x04e34;&#x05e8a;&#x09884;&#x0540e;&#x03002;</p><p xml:lang="zh">&#x06458;&#x08981;</p><p xml:lang="zh"><bold><italic>&#x080cc;&#x0666f;</italic></bold>. Simtuzumab&#x0662f;&#x08d56;&#x06c28;&#x09170;&#x06c27;&#x05316;&#x09176;&#x06837;&#x086cb;&#x0767d;&#x02010;2&#x0ff08;LOXL2&#x0ff09;&#x07684;&#x04e00;&#x079cd;&#x04eba;&#x06e90;&#x05316;IgG4&#x05355;&#x0514b;&#x09686;&#x06297;&#x04f53;, &#x05728;&#x04f53;&#x05916;&#x053ef;&#x0963b;&#x06b62;&#x07ed3;&#x076f4;&#x080a0;&#x0764c;&#x0ff08;CRC&#x0ff09;&#x07ec6;&#x080de;&#x053d1;&#x0751f;&#x04fc3;&#x07ed3;&#x07f14;&#x07ec4;&#x07ec7;&#x0589e;&#x0751f;&#x06027;&#x053cd;&#x05e94;</p><p xml:lang="zh"><bold><italic>&#x065b9;&#x06cd5;</italic></bold>. &#x0643a;&#x05e26;<italic>KRAS</italic>&#x0ff08;Kirsten&#x05927;&#x09f20;&#x08089;&#x07624;&#x075c5;&#x06bd2;&#x0764c;&#x057fa;&#x056e0;&#x0540c;&#x06e90;&#x07269;&#x0ff09;&#x07a81;&#x053d8;&#x07684;&#x08f6c;&#x079fb;&#x06027;CRC&#x060a3;&#x08005;&#x0968f;&#x0673a;&#x063a5;&#x053d7;5&#x02010;&#x06c1f;&#x05c3f;&#x05627;&#x05576;&#x03001;&#x07532;&#x09170;&#x056db;&#x06c22;&#x053f6;&#x09178;&#x0548c;&#x04f0a;&#x07acb;&#x066ff;&#x05eb7;&#x0ff08;FOLFIRI&#x0ff09;&#x04e8c;&#x07ebf;&#x06cbb;&#x07597;&#x08054;&#x05408;Simtuzumab 200&#x06216;700 mg&#x06216;&#x08005;&#x08054;&#x05408;&#x05b89;&#x06170;&#x05242;&#x06cbb;&#x07597;, &#x06bcf;2&#x05468;&#x07ed9;&#x0836f;&#x04e00;&#x06b21;, 28&#x05929;&#x04e3a;&#x04e00;&#x04e2a;&#x05468;&#x0671f;&#x03002;&#x08bc4;&#x04f30;&#x065e0;&#x08fdb;&#x05c55;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;PFS&#x0ff09;&#x03001;&#x0603b;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;OS&#x0ff09;&#x03001;&#x05ba2;&#x089c2;&#x07f13;&#x089e3;&#x07387;&#x0ff08;ORR&#x0ff09;&#x0548c;&#x05b89;&#x05168;&#x06027;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x0679c;</italic></bold>. &#x0603b;&#x08ba1;249&#x04f8b;&#x060a3;&#x08005;&#x0968f;&#x0673a;&#x063a5;&#x053d7;FOLFIRI/Simtuzumab 700 mg&#x0ff08;n=84&#x0ff09;&#x03001;FOLFIRI/Simtuzumab 200 mg&#x0ff08;n=85&#x0ff09;&#x06216;FOLFIRI/&#x05b89;&#x06170;&#x05242;&#x0ff08;n=80&#x0ff09;&#x06cbb;&#x07597;&#x03002;&#x05206;&#x0522b;&#x08fdb;&#x0884c;&#x04e3a;&#x0671f;5.1&#x04e2a;&#x06708;&#x03001;3.8&#x04e2a;&#x06708;&#x0548c;5.5&#x04e2a;&#x06708;&#x07684;&#x04e2d;&#x04f4d;&#x0968f;&#x08bbf;&#x0540e;, &#x076f8;&#x05e94;&#x06cbb;&#x07597;&#x07ec4;&#x07684;&#x04e2d;&#x04f4d;PFS&#x05206;&#x0522b;&#x04e3a;5.5&#x04e2a;&#x06708;[&#x06821;&#x06b63;HR&#x0ff08;95% CI&#x0ff09;, &#x04e0e;&#x05b89;&#x06170;&#x05242;&#x06bd4;&#x08f83;&#x07684;<italic>p</italic>&#x0503c;&#x0ff1a;1.32&#x0ff08;0.92, 1.89&#x0ff09;, <italic>p</italic>=0.10]&#x03001;5.4&#x04e2a;&#x06708;[1.45&#x0ff08;1.01, 2.06&#x0ff09;, <italic>p</italic>=0.04]&#x0548c;5.8&#x04e2a;&#x06708;&#x03002;&#x04e2d;&#x04f4d;OS&#x05206;&#x0522b;&#x04e3a;11.4&#x04e2a;&#x06708;[1.23&#x0ff08;0.80, 1.91&#x0ff09;, <italic>p</italic>=0.25]&#x03001;10.5&#x04e2a;&#x06708;[1.50&#x0ff08;0.98, 2.30&#x0ff09;, <italic>p</italic>=0.06]&#x0548c;16.3&#x04e2a;&#x06708;&#x03002;ORR&#x05206;&#x0522b;&#x04e3a;11.9%&#x03001;5.9%&#x0548c;10%&#x03002;&#x08f6c;&#x079fb;&#x06027;<italic>KRAS</italic>&#x07a81;&#x053d8;CRC&#x060a3;&#x08005;&#x053ef;&#x04ee5;&#x08010;&#x053d7;Simtuzumab</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x08bba;</italic></bold>. Simtuzumab&#x04e0e;FOLFIRI&#x08054;&#x07528;&#x0672a;&#x06539;&#x05584;&#x08f6c;&#x079fb;&#x06027;<italic>KRAS</italic>&#x07a81;&#x053d8;CRC&#x060a3;&#x08005;&#x07684;&#x04e34;&#x05e8a;&#x09884;&#x0540e;&#x03002;</p></trans-abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec sec-type="discussion" id="onco12049-sec-0006"><title>Discussion</title><p>Stroma in the tumor environment is associated with higher numbers of activated fibroblasts, which contribute to the desmoplastic reaction. Tumor&#x02010;associated activated fibroblasts secrete oncogenic growth factors, produce extracellular matrix (ECM), and promote epithelial cell transformation. Lysyl oxidase&#x02010;like 2 (LOXL2), an extracellular matrix enzyme that remodels ECM, is thought to contribute to the maintenance of the pathologic stromal microenvironment in cancer and fibrotic diseases and to promote tumor angiogenesis and metastatic progression. LOXL2 is expressed in desmoplastic tumors, including CRC, with no expression in the adjacent nonneoplastic areas. Simtuzumab, a humanized IgG4 monoclonal antibody to LOXL2, inhibits its enzymatic activity.</p><p>In preclinical studies with antibody precursors to simtuzumab, inhibition of LOXL2 expression reduced the number of activated fibroblasts, decreased ECM deposition, inhibited angiogenesis, and prevented tumor cell invasion and metastases. In a phase I study in patients with advanced solid tumors, simtuzumab reduced the size of several tumors in some patients.</p><p>We assessed the additive efficacy of simtuzumab in a multicenter, randomized, double&#x02010;blind, placebo&#x02010;controlled, phase II study of simtuzumab or placebo in combination with FOLFIRI as a second&#x02010;line therapy in patients with metastatic <italic>KRAS</italic>&#x02010;mutant adenocarcinoma of the colon or rectum not amenable to complete surgical resection, who previously failed fluoropyrimidine and oxaliplatin therapy (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> #NCT01479465). Eligible patients had metastatic disease; Eastern Cooperative Oncology Group performance status (ECOG PS) &#x02264;2; adequate bone marrow, hepatic, and renal function; and estimated life expectancy &#x0003e;3 months. Patients were randomized 1:1:1 to receive intravenous FOLFIRI in combination with 700 mg simtuzumab, 200 mg simtuzumab, or placebo every 2 weeks in cycles of 28 days until disease progression or unacceptable toxicity; randomization was stratified by ECOG PS 0 versus &#x0003e;0. From December 2011 to March 2014, 255 patients were enrolled and 249 patients received at least 1 cycle of study drug, with a median number of 6 cycles. Overall, 231 (90.6%) patients discontinued study drug, mainly due to disease progression (185 [72.5%]) and adverse events (12 [4.7%]). The majority of patients were male (128/249, 51.4%) and white (212/249, 85.1%), with a mean (range) age of 60.5 (22.0&#x02013;85.0) years and a mean 20.3 months from diagnosis. A sequential stepwise hypothesis and a Hochberg testing procedure were used to compare between the two simtuzumab dosing groups versus placebo for PFS, OS, and ORR. The efficacy analyses failed to demonstrate improvement in clinical endpoints upon the addition of simtuzumab to FOLFIRI chemotherapy (Table <xref rid="onco12049-tbl-0001" ref-type="table">1</xref>). Results from additional sensitivity analyses were consistent with the primary analyses. The safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group. Among seven adverse events that led to death, a case of febrile neutropenia was deemed related to treatment with FOLFIRI.
</p></sec><sec id="onco12049-sec-0007"><title>Trial Information</title><p><def-list id="onco12049-lp-0001"><def-item><term id="onco12049-li-1202"><bold>Disease</bold></term><def id="onco12049-li-1203"><p>Colorectal cancer</p></def></def-item><def-item><term id="onco12049-li-1204"><bold>Stage of disease/treatment</bold></term><def id="onco12049-li-1205"><p>Metastatic/Advanced</p></def></def-item><def-item><term id="onco12049-li-1206"><bold>Prior therapy</bold></term><def id="onco12049-li-1207"><p>First&#x02010;line oxaliplatin&#x02010; and fluoropyrimidine&#x02010;containing regimen</p></def></def-item><def-item><term id="onco12049-li-1208"><bold>Type of study &#x02010; 1</bold></term><def id="onco12049-li-1209"><p>Phase II</p></def></def-item><def-item><term id="onco12049-li-1210"><bold>Type of study &#x02010; 2</bold></term><def id="onco12049-li-1211"><p>Randomized</p></def></def-item><def-item><term id="onco12049-li-1212"><bold>ORR</bold></term><def id="onco12049-li-1213"><p>Difference in ORR from placebo, stratified (primary) analysis was 2.0% for the simtuzumab 700 mg arm (p&#x02009;=&#x02009;.69), and &#x02212;4.1% for the simtuzumab 200 mg arm (p&#x02009;=&#x02009;.33).</p></def></def-item><def-item><term id="onco12049-li-1214"><bold>PFS</bold></term><def id="onco12049-li-1215"><p>The median PFS was 5.5 months, (HR 1.32, 0.92, 1.89; p&#x02009;=&#x02009;.10) in the 700 mg simtuzumab arm, 5.4 months (HR 1.45, 1.01, 2.06, p&#x02009;=&#x02009;.04) in the 200 mg simtuzumab arm, and 5.8 month in the control arm</p></def></def-item><def-item><term id="onco12049-li-1216"><bold>Primary endpoint</bold></term><def id="onco12049-li-1217"><p>Progression&#x02010;free survival</p></def></def-item><def-item><term id="onco12049-li-1218"><bold>Secondary endpoint</bold></term><def id="onco12049-li-1219"><p>Overall response rate</p></def></def-item><def-item><term id="onco12049-li-1220"><bold>Secondary endpoint</bold></term><def id="onco12049-li-1221"><p>Overall survival</p></def></def-item><def-item><term id="onco12049-li-1222"><bold>Secondary endpoint</bold></term><def id="onco12049-li-1223"><p>Safety</p></def></def-item><def-item><term id="onco12049-li-1224"><bold>Additional details of endpoints or study design</bold></term><def id="onco12049-li-1225"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1226">Patients had to have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1, defined with all of following criteria: (a) lesions accurately measured in at least one dimension, (b) longest diameter in the plane of measurement was recorded, and (c) minimum size of 10 mm if computed tomography slice thickness &#x02264;5 mm; if thickness was &#x0003e;5 mm, then the minimum size of measurable lesions was twice the slice thickness. Patients were excluded if they had more than one prior chemotherapy regimen for stage IV/metastatic colorectal cancer; underwent an experimental medical treatment within 30 days prior to study entry; received an antitumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) within 21 days prior to randomization; or had cerebral metastases, uncontrolled hypertension, coronary heart disease, liver disease, or uncontrolled infection. Treatments were administered on day 1 and 15 of each 28&#x02010;day cycle. Simtuzumab or placebo was given by IV infusion over 30 minutes. FOLFIRI consisted of 200 mg/m<sup>2</sup> leucovorin or 400 mg/m<sup>2</sup> dl&#x02010;leucovorin administered as a 2&#x02010;hour infusion; 180 mg/m<sup>2</sup> irinotecan given as a 90&#x02010;minute infusion in 500 mL dextrose 5% via a Y&#x02010;connector; and 400 mg/m<sup>2</sup> fluorouracil bolus followed by a 46&#x02010;hour infusion of 2,400 mg/m<sup>2</sup> fluorouracil. Efficacy was analyzed in all randomized patients who received at least one dose of study drug (full analysis set [FAS]) based on investigator assessment. Safety analysis set included patients in the FAS population grouped for analyses with treatment assignments designated according to the actual study drug received. Safety assessments included the incidence of adverse events (AEs), infusion site reactions, and clinically relevant changes in laboratory values and vital signs. AEs were coded according to MedDRA version 17.1 and graded per National Cancer Institute Common Toxicity Criteria (CTCAE version 4.03). Overall response rate (ORR) was assessed by the investigator per RECIST v1.1 as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The difference in PFS and OS from placebo was assessed using Kaplan&#x02013;Meier methods and the stratified log&#x02010;rank test, adjusted for the stratification factor ECOG 0 or &#x0003e;0 at randomization. Cochran&#x02013;Mantel&#x02013;Haenszel test was used for calculating difference in ORR from placebo. A sequential stepwise hypothesis and a Hochberg testing procedure were used to compare between simtuzumab dosing groups versus placebo for PFS, OS, and ORR, per investigator assessment. A number of sensitivity analyses for PFS, OS, and ORR were also performed to confirm the results of primary analyses. A total of 185 PFS events had to be observed in this study to detect a hazard ratio of 0.6 with approximately 90% power at a two&#x02010;sided 0.05 significance level based on Hochberg procedure to claim that at least one of the simtuzumab treatment groups improved PFS significantly compared with placebo. The estimated sample size was 255 patients.</term><def id="onco12049-li-1227"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1228"><bold>Investigator's analysis</bold></term><def id="onco12049-li-1229"><p>Level of activity did not meet planned endpoint.</p></def></def-item></def-list>
</p></sec><sec id="onco12049-sec-0008"><title>Drug Information Control Arm</title><p><def-list id="onco12049-lp-0002"><def-item><term id="onco12049-li-1230">Generic/Working name</term><def id="onco12049-li-1231"><p>Folinic acid (leucovorin)</p></def></def-item><def-item><term id="onco12049-li-1232">Drug type</term><def id="onco12049-li-1233"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1234">Drug class</term><def id="onco12049-li-1235"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12049-li-1236">Dose</term><def id="onco12049-li-1237"><p>200 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12049-li-1238">Route</term><def id="onco12049-li-1239"><p>IV over 2 hours</p></def></def-item><def-item><term id="onco12049-li-1240">Schedule of administration</term><def id="onco12049-li-1241"><p>Day 1 and 15 of each 28&#x02010;day cycle</p></def></def-item><def-item><term id="onco12049-li-1242">Drug 2</term><def id="onco12049-li-1243"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1244">Generic/working name</term><def id="onco12049-li-1245"><p>5&#x02010;FU</p></def></def-item><def-item><term id="onco12049-li-1246">Drug type</term><def id="onco12049-li-1247"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1248">Drug class</term><def id="onco12049-li-1249"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12049-li-1250">Dose</term><def id="onco12049-li-1251"><p>2,400 mg/m<sup>2</sup> (bolus 400 mg/m<sup>2</sup>)</p></def></def-item><def-item><term id="onco12049-li-1252">Route</term><def id="onco12049-li-1253"><p>Continuous intravenous infusion (CIV) over 46 hours</p></def></def-item><def-item><term id="onco12049-li-1254">Schedule of administration</term><def id="onco12049-li-1255"><p>Day 1 and 15 of each 28-day cycle</p></def></def-item><def-item><term id="onco12049-li-1256">Drug 3</term><def id="onco12049-li-1257"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1258">Generic/working name</term><def id="onco12049-li-1259"><p>Irinotecan</p></def></def-item><def-item><term id="onco12049-li-1260">Drug type</term><def id="onco12049-li-1261"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1262">Drug class</term><def id="onco12049-li-1263"><p>Inhibitor of topoisomerase I</p></def></def-item><def-item><term id="onco12049-li-1264">Dose</term><def id="onco12049-li-1265"><p>180 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12049-li-1266">Route</term><def id="onco12049-li-1267"><p>IV over 1.5 hours</p></def></def-item><def-item><term id="onco12049-li-1268">Schedule of administration</term><def id="onco12049-li-1269"><p>Day 1 and 15 of each 28-day cycle</p></def></def-item></def-list>
</p></sec><sec id="onco12049-sec-2001"><title>Drug Information Experimental Arm A: Simtuzumab 200 mg</title><p><def-list id="onco12049-lp-1001"><def-item><term id="onco12049-li-1270">Drug 1</term><def id="onco12049-li-1271"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1272">Generic/working name</term><def id="onco12042-li-1273"><p>Simtuzumab (GS&#x02010;6624)</p></def></def-item><def-item><term id="onco12049-li-1274">Company name</term><def id="onco12042-li-1275"><p>Gilead Sciences, Inc.</p></def></def-item><def-item><term id="onco12049-li-1276">Drug type</term><def id="onco12042-li-1277"><p>Antibody</p></def></def-item><def-item><term id="onco12049-li-1278">Drug class</term><def id="onco12042-li-1279"><p>Inhibitor of lysyl oxidase-like 2 enzyme</p></def></def-item><def-item><term id="onco12049-li-1280">Dose</term><def id="onco12042-li-1281"><p>200 mg per flat dose</p></def></def-item><def-item><term id="onco12049-li-1282">Route</term><def id="onco12042-li-1283"><p>IV</p></def></def-item><def-item><term id="onco12049-li-1284">Schedule of administration</term><def id="onco12042-li-1285"><p>Day 1 and 15 of each 28&#x02010;day cycle</p></def></def-item><def-item><term id="onco12049-li-1286">Drug 2</term><def id="onco12042-li-1287"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1288">Generic/working name</term><def id="onco12042-li-1289"><p>Leucovorin</p></def></def-item><def-item><term id="onco12049-li-1290">Drug type</term><def id="onco12042-li-1291"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1292">Drug class</term><def id="onco12042-li-1293"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12049-li-1294">Dose</term><def id="onco12042-li-1295"><p>200 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12049-li-1296">Route</term><def id="onco12042-li-1297"><p>IV over 2 hours</p></def></def-item><def-item><term id="onco12049-li-1298">Schedule of administration</term><def id="onco12042-li-1299"><p>Day 1 and 15 of each 28&#x02010;day cycle</p></def></def-item><def-item><term id="onco12049-li-1300">Drug 3</term><def id="onco12042-li-1301"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1302">Generic/working name</term><def id="onco12042-li-1303"><p>5&#x02010;FU</p></def></def-item><def-item><term id="onco12049-li-1304">Drug type</term><def id="onco12042-li-1305"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1306">Drug class</term><def id="onco12042-li-1307"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12049-li-1308">Dose</term><def id="onco12042-li-1309"><p>2,400 mg/m<sup>2</sup> (bolus 400 mg/m<sup>2</sup>)</p></def></def-item><def-item><term id="onco12049-li-1310">Route</term><def id="onco12042-li-1311"><p>Continuous intravenous infusion (CIV) over 46 hours</p></def></def-item><def-item><term id="onco12049-li-1312">Schedule of administration</term><def id="onco12042-li-1313"><p>Day 1 and 15 of each 28-day cycle</p></def></def-item><def-item><term id="onco12049-li-1314">Drug 4</term><def id="onco12042-li-1315"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1316">Generic/working name</term><def id="onco12042-li-1317"><p>Irinotecan</p></def></def-item><def-item><term id="onco12049-li-1318">Drug type</term><def id="onco12042-li-1319"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1320">Drug class</term><def id="onco12042-li-1321"><p>Inhibitor of topoisomerase I</p></def></def-item><def-item><term id="onco12049-li-1322">Dose</term><def id="onco12042-li-1323"><p>180 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12049-li-1324">Route</term><def id="onco12042-li-1325"><p>IV over 1.5 hours</p></def></def-item><def-item><term id="onco12049-li-1326">Schedule of administration</term><def id="onco12042-li-1327"><p>Day 1 and 15 of each 28-day cycle</p></def></def-item></def-list>
</p></sec><sec id="onco12049-sec-2011"><title>Drug Information Experimental Arm B: Simtuzumab 700 mg</title><p><def-list id="onco12041-lp-0001"><def-item><term id="onco12049-li-1328">Drug 1</term><def id="onco12042-li-1329"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1330">Generic/working name</term><def id="onco12042-li-1331"><p>Simtuzumab (GS&#x02010;6624)</p></def></def-item><def-item><term id="onco12049-li-1332">Company name</term><def id="onco12042-li-1333"><p>Gilead Sciences, Inc.</p></def></def-item><def-item><term id="onco12049-li-1334">Drug type</term><def id="onco12042-li-1335"><p>Antibody</p></def></def-item><def-item><term id="onco12049-li-1336">Drug class</term><def id="onco12042-li-1337"><p>Inhibitor of lysyl oxidase-like 2 enzyme</p></def></def-item><def-item><term id="onco12049-li-1338">Dose</term><def id="onco12042-li-1339"><p>700 mg per flat dose</p></def></def-item><def-item><term id="onco12049-li-1340">Route</term><def id="onco12042-li-1341"><p>IV</p></def></def-item><def-item><term id="onco12049-li-1342">Schedule of administration</term><def id="onco12042-li-1343"><p>Day 1 and 15 of each 28&#x02010;day cycle</p></def></def-item><def-item><term id="onco12049-li-1344">Drug 2</term><def id="onco12042-li-1345"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1346">Generic/working name</term><def id="onco12042-li-1347"><p>Leucovorin</p></def></def-item><def-item><term id="onco12049-li-1348">Drug type</term><def id="onco12042-li-1349"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1350">Drug class</term><def id="onco12042-li-1351"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12049-li-1352">Dose</term><def id="onco12042-li-1353"><p>200 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12049-li-1354">Route</term><def id="onco12042-li-1355"><p>IV over 2 hours</p></def></def-item><def-item><term id="onco12049-li-1356">Schedule of administration</term><def id="onco12042-li-1357"><p>Day 1 and 15 of each 28&#x02010;day cycle</p></def></def-item><def-item><term id="onco12049-li-1358">Drug 3</term><def id="onco12042-li-1359"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1360">Generic/working name</term><def id="onco12042-li-1361"><p>5&#x02010;FU</p></def></def-item><def-item><term id="onco12049-li-1362">Drug type</term><def id="onco12042-li-1363"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1364">Drug class</term><def id="onco12042-li-1365"><p>Antimetabolite</p></def></def-item><def-item><term id="onco12049-li-1366">Dose</term><def id="onco12042-li-1367"><p>2,400 mg/m<sup>2</sup> (bolus 400 mg/m<sup>2</sup>)</p></def></def-item><def-item><term id="onco12049-li-1368">Route</term><def id="onco12042-li-1369"><p>Continuous intravenous infusion (CIV) over 46 hours</p></def></def-item><def-item><term id="onco12049-li-1370">Schedule of administration</term><def id="onco12042-li-1371"><p>Day 1 and 15 of each 28-day cycle</p></def></def-item><def-item><term id="onco12049-li-1372">Drug 4</term><def id="onco12042-li-1373"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1374">Generic/working name</term><def id="onco12042-li-1375"><p>Irinotecan</p></def></def-item><def-item><term id="onco12049-li-1376">Drug type</term><def id="onco12042-li-1377"><p>Small molecule</p></def></def-item><def-item><term id="onco12049-li-1378">Drug class</term><def id="onco12042-li-1379"><p>Inhibitor of topoisomerase I</p></def></def-item><def-item><term id="onco12049-li-1380">Dose</term><def id="onco12042-li-1381"><p>180 mg/m<sup>2</sup></p></def></def-item><def-item><term id="onco12049-li-1382">Route</term><def id="onco12042-li-1383"><p>IV over 1.5 hours</p></def></def-item><def-item><term id="onco12049-li-1384">Schedule of administration</term><def id="onco12042-li-1385"><p>Day 1 and 15 of each 28-day cycle</p></def></def-item></def-list>
</p></sec><sec id="onco12049-sec-0009"><title>Patient Characteristics</title><p><def-list id="onco12049-lp-0003"><def-item><term id="onco12049-li-1386">Number of patients, male</term><def id="onco12049-li-1387"><p>128</p></def></def-item><def-item><term id="onco12049-li-1388">Number of patients, female</term><def id="onco12049-li-1389"><p>121</p></def></def-item><def-item><term id="onco12049-li-1390"><bold>Stage</bold></term><def id="onco12049-li-1391"><p>Advanced, metastatic, stage IV</p></def></def-item><def-item><term id="onco12049-li-1392"><bold>Age</bold></term><def id="onco12049-li-1393"><p>Median (range), years: 700 mg simtuzumab, 61 (22&#x02013;78); 200 mg simtuzumab, 64 (31&#x02013;83); placebo, 60.5 (32&#x02013;85)</p></def></def-item><def-item><term id="onco12049-li-1394"><bold>Number of prior systemic therapies</bold></term><def id="onco12049-li-1395"><p>1, first&#x02010;line oxaliplatin&#x02010; and fluoropyrimidine&#x02010;containing regimen</p></def></def-item><def-item><term id="onco12049-li-1396"><bold>Performance status: ECOG</bold></term><def id="onco12049-li-1397"><p>0 &#x02014; 118</p><p>1 &#x02014; 126</p><p>2 &#x02014; 5</p></def></def-item></def-list>
</p></sec><sec id="onco12049-sec-0010"><title>Primary Assessment Method</title><p><def-list id="onco12049-lp-0004"><def-item><term id="onco12049-li-1398">Control Arm:</term><def id="onco12049-li-1399"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1400">Number of patients enrolled</term><def id="onco12049-li-1401"><p>84</p></def></def-item><def-item><term id="onco12049-li-1402">Number of patients evaluable for toxicity</term><def id="onco12049-li-1403"><p>80</p></def></def-item><def-item><term id="onco12049-li-1404">Number of patients evaluated for efficacy</term><def id="onco12049-li-1405"><p>80</p></def></def-item><def-item><term id="onco12049-li-1406">Response assessment CR</term><def id="onco12049-li-1407"><p>n&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12049-li-1408">Response assessment PR</term><def id="onco12049-li-1409"><p>n&#x02009;=&#x02009;8 (10%)</p></def></def-item><def-item><term id="onco12049-li-1410">Response assessment SD</term><def id="onco12049-li-1411"><p>n&#x02009;=&#x02009;53 (66%)</p></def></def-item><def-item><term id="onco12049-li-1412">Response assessment PD</term><def id="onco12049-li-1413"><p>n&#x02009;=&#x02009;17 (21%)</p></def></def-item><def-item><term id="onco12049-li-1414">Response assessment OTHER</term><def id="onco12049-li-1415"><p>n&#x02009;=&#x02009;2 (3%)</p></def></def-item><def-item><term id="onco12049-li-1416">(Median) duration assessments PFS</term><def id="onco12049-li-1417"><p>5.8 months, CI: 4.9&#x02013;9.0</p></def></def-item><def-item><term id="onco12049-li-1418">(Median) duration assessments OS</term><def id="onco12049-li-1419"><p>16.3 months, CI: 12.0&#x02013;19.5</p></def></def-item><def-item><term id="onco12049-li-1420">Experimental Arm A: Simtuzumab 200 mg</term><def id="onco12049-li-1421"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1422">Number of patients enrolled</term><def id="onco12049-li-1423"><p>86</p></def></def-item><def-item><term id="onco12049-li-1424">Number of patients evaluable for toxicity</term><def id="onco12049-li-1425"><p>85</p></def></def-item><def-item><term id="onco12049-li-1426">Number of patients evaluated for efficacy</term><def id="onco12049-li-1427"><p>85</p></def></def-item><def-item><term id="onco12049-li-1428">Response assessment CR</term><def id="onco12049-li-1429"><p>n&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12049-li-1430">Response assessment PR</term><def id="onco12049-li-1431"><p>n&#x02009;=&#x02009;5 (6%)</p></def></def-item><def-item><term id="onco12049-li-1432">Response assessment SD</term><def id="onco12049-li-1433"><p>n&#x02009;=&#x02009;50 (59%)</p></def></def-item><def-item><term id="onco12049-li-1434">Response assessment PD</term><def id="onco12049-li-1435"><p>n&#x02009;=&#x02009;23 (27%)</p></def></def-item><def-item><term id="onco12049-li-1436">Response assessment OTHER</term><def id="onco12049-li-1437"><p>n&#x02009;=&#x02009;7 (8%)</p></def></def-item><def-item><term id="onco12049-li-1438">(Median) duration assessments PFS</term><def id="onco12049-li-1439"><p>5.4 months, CI: 3.4&#x02013;5.6</p></def></def-item><def-item><term id="onco12049-li-1440">(Median) duration assessments OS</term><def id="onco12049-li-1441"><p>10.5 months, CI: 9.2&#x02013;12.6</p></def></def-item><def-item><term id="onco12049-li-1442">Experimental Arm B: Simtuzumab 700 mg</term><def id="onco12049-li-1443"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12049-li-1444">Number of patients enrolled</term><def id="onco12049-li-1445"><p>85</p></def></def-item><def-item><term id="onco12049-li-1446">Number of patients evaluable for toxicity</term><def id="onco12049-li-1447"><p>84</p></def></def-item><def-item><term id="onco12049-li-1448">Number of patients evaluated for efficacy</term><def id="onco12049-li-1449"><p>84</p></def></def-item><def-item><term id="onco12049-li-1450">Response assessment CR</term><def id="onco12049-li-1451"><p>n&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12049-li-1452">Response assessment PR</term><def id="onco12049-li-1453"><p>n&#x02009;=&#x02009;10 (12%)</p></def></def-item><def-item><term id="onco12049-li-1454">Response assessment SD</term><def id="onco12049-li-1455"><p>n&#x02009;=&#x02009;49 (58%)</p></def></def-item><def-item><term id="onco12049-li-1456">Response assessment PD</term><def id="onco12049-li-1457"><p>n&#x02009;=&#x02009;23 (27%)</p></def></def-item><def-item><term id="onco12049-li-1458">Response assessment OTHER</term><def id="onco12049-li-1459"><p>n&#x02009;=&#x02009;2 (2%)</p></def></def-item><def-item><term id="onco12049-li-1460">(Median) duration assessments PFS</term><def id="onco12049-li-1461"><p>5.5 months, CI: 4.0&#x02013;7.1</p></def></def-item><def-item><term id="onco12049-li-1462">(Median) duration assessments OS</term><def id="onco12049-li-1463"><p>11.4 months, CI: 9.7&#x02013;15.6</p></def></def-item></def-list>
</p></sec><sec id="onco12049-sec-1010"><title>Adverse Events Control Arm</title><p>
<table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12049-tbl-0008"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12049-note-0010"><p>*NC/NA No change from baseline/no adverse event</p></fn><fn id="onco12049-note-0011"><p>Adverse events that occurred in &#x02265;10% of patients. <italic>n</italic>&#x02009;=&#x02009;80, safety analysis set. Clinical and laboratory adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 16.1 and graded using the National Cancer Institute Common Toxicity Criteria (CTCAE version 4.03).</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="nlm-table-wrap-2" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-3" specific-use="sourcefile-name" xlink:href="onco12049-tbl-0009"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12049-note-0412"><p>SAEs deemed related to simtuzumab/placebo. As this was a double&#x02010;blind study, the SAEs considered related to simtuzumab were recorded for both treatment arms. SAEs related to FOLFIRI were not collected. <italic>n</italic>&#x02009;=&#x02009;80, safety analysis set.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="onco12049-sec-1410"><title>Adverse Events Both Experimental Arms</title><p>
<table-wrap id="nlm-table-wrap-3" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-5" specific-use="sourcefile-name" xlink:href="onco12049-tbl-0010"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12049-note-0013"><p>*NC/NA No change from baseline/no adverse event</p></fn><fn id="onco12049-note-0014"><p>Adverse events that occurred in &#x02265;10% of patients. <italic>n</italic>&#x02009;=&#x02009;169, safety analysis set. Clinical and laboratory adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 16.1 and graded using the National Cancer Institute Common Toxicity Criteria (CTCAE version 4.03).</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="nlm-table-wrap-4" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-7" specific-use="sourcefile-name" xlink:href="onco12049-tbl-0011"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12049-note-0301"><p>SAEs deemed related to simtuzumab. SAEs related to FOLFIRI were not collected. <italic>n</italic>&#x02009;=&#x02009;169, safety analysis set.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="onco12049-sec-0011"><title>Assessment, Analysis, and Discussion</title><p><def-list id="onco12049-lp-0005"><def-item><term id="onco12049-li-1464">Completion</term><def id="onco12049-li-1465"><p>Study completed</p></def></def-item><def-item><term id="onco12049-li-1466">Pharmacokinetics/Pharmacodynamics</term><def id="onco12049-li-1467"><p>Not Collected</p></def></def-item><def-item><term id="onco12049-li-1468">Investigator's Assessment</term><def id="onco12049-li-1469"><p>Level of activity did not meet planned endpoint</p></def></def-item></def-list>
</p></sec><sec id="onco12049-sec-0012"><p>Colorectal cancer (CRC) accounts for 9.7% of all incident cancers worldwide and is the fourth leading cause of cancer mortality [<xref rid="onco12049-bib-0001" ref-type="ref">1</xref>]. One of the frequent genetic mutations in CRC is in the <italic>KRAS</italic> gene in the chromosomal instability pathway [<xref rid="onco12049-bib-0002" ref-type="ref">2</xref>]. <italic>KRAS</italic> mutation&#x02010;positive patients do not respond to anti&#x02010;epidermal growth factor receptor antibody therapy [<xref rid="onco12049-bib-0003" ref-type="ref">3</xref>] and have poorer survival than patients with the <italic>KRAS</italic> wild&#x02010;type gene [<xref rid="onco12049-bib-0004" ref-type="ref">4</xref>]. The currently available therapies for advanced <italic>KRAS</italic>&#x02010;mutated CRC include chemotherapy alone or in combination with antiangiogenic antibodies such as bevacizumab, aflibercept, or ramucirumab [<xref rid="onco12049-bib-0005" ref-type="ref">5</xref>]. New therapies are urgently needed for this patient population.</p><p>Activated stroma in the tumor environment is associated with higher numbers of activated fibroblasts, which contribute to the desmoplastic reaction [<xref rid="onco12049-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12049-bib-0007" ref-type="ref">7</xref>]. Tumor&#x02010;associated activated fibroblasts secrete oncogenic growth factors, produce extracellular matrix (ECM), and promote epithelial cell transformation [<xref rid="onco12049-bib-0007" ref-type="ref">7</xref>], [<xref rid="onco12049-bib-0008" ref-type="ref">8</xref>]. Lysyl oxidase&#x02010;like 2 (LOXL2), an enzyme that remodels the ECM, contributes to the maintenance of the pathologic stromal microenvironment in cancer and fibrotic diseases [<xref rid="onco12049-bib-0009" ref-type="ref">9</xref>] and promotes tumor angiogenesis [<xref rid="onco12049-bib-0010" ref-type="ref">10</xref>] and metastatic progression [<xref rid="onco12049-bib-0011" ref-type="ref">11</xref>]. LOXL2 is expressed in desmoplastic tumors, including CRC, with no expression in the adjacent nonneoplastic areas [<xref rid="onco12049-bib-0008" ref-type="ref">8</xref>], [<xref rid="onco12049-bib-0012" ref-type="ref">12</xref>].</p><p>Simtuzumab, a humanized IgG4 monoclonal antibody against LOXL2, inhibits its enzymatic activity [<xref rid="onco12049-bib-0013" ref-type="ref">13</xref>]. In preclinical studies with antibody precursors to simtuzumab, inhibition of LOXL2 expression reduced numbers of activated fibroblasts, decreased ECM deposition [<xref rid="onco12049-bib-0009" ref-type="ref">9</xref>], inhibited angiogenesis [<xref rid="onco12049-bib-0014" ref-type="ref">14</xref>], and prevented tumor cell invasion and metastases [<xref rid="onco12049-bib-0015" ref-type="ref">15</xref>]. Of note, in preclinical models, simtuzumab had better efficacy in <italic>KRAS</italic> mutant cell lines (Gilead Sciences, Inc., data on file). In a phase I study in patients with advanced solid tumors, single agent simtuzumab reduced the size of several tumors in select patients [<xref rid="onco12049-bib-0016" ref-type="ref">16</xref>].</p><p>In a multicenter, randomized, double&#x02010;blind, placebo&#x02010;controlled phase II study, we evaluated the efficacy of simtuzumab or placebo in combination with FOLFIRI as a second&#x02010;line therapy in patients with metastatic <italic>KRAS</italic>&#x02010;mutant CRC who progressed following oxaliplatin&#x02010; and fluoropyrimidine&#x02010;containing first&#x02010;line therapy (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> #NCT01479465).</p><p>The key endpoints included progression&#x02010;free survival (PFS), overall survival (OS), objective response rate (ORR) per RECIST v1.1, and safety. Enrolled patients had stage IV disease; ECOG PS &#x02264;2; adequate bone marrow, hepatic, and renal function; and estimated life expectancy &#x0003e;3 months. Patients were randomized 1:1:1 to receive intravenous FOLFIRI in combination with simtuzumab or placebo until disease progression or unacceptable toxicity; randomization was stratified by Eastern Cooperative Oncology Group performance status (ECOG PS) 0 vs &#x0003e;0. Patients were scheduled for 2 visits per cycle and a computed tomography (CT) or magnetic resonance imaging (MRI) scan every 8 weeks.</p><p>From December 2011 to March 2014, 255 patients were randomized, 249 patients received at least one 28&#x02010;day cycle of study drug (full analysis set [FAS]), and 233 (94%) patients received &#x02265;2 cycles, with a median number of 6 cycles. The majority of enrolled patients were male (128/249, 51.4%) and white (212/249, 85.1%), with a mean (range) age of 60.5 (22.0&#x02013;85.0) years (Table <xref rid="onco12049-tbl-0002" ref-type="table">2</xref>). The mean (SD) time since first diagnosis of colorectal cancer was 20.3 (20.31) months. In total, 42% of patients had 3 or more target lesions at baseline. The most common target lesion sites included liver (73%), lung (45%), and lymph nodes (16%) (Table <xref rid="onco12049-tbl-0002" ref-type="table">2</xref>).</p><p>Overall, 231 (90.6%) patients had discontinued study, mainly due to disease progression (185 [72.5%]) and adverse events (12 [4.7%]). A sequential stepwise hypothesis and a Hochberg testing procedure were used to compare between the two simtuzumab dosing groups versus placebo for PFS, OS, and ORR. A number of sensitivity analyses were also conducted for PFS, OS, and ORR to confirm the results of the primary analyses. The study failed to reach any of the prespecified efficacy endpoints. Median PFS for FOLFIRI/simtuzumab 700 mg, FOLFIRI/simtuzumab 200 mg, and FOLFIRI/placebo was 5.5 months (adjusted hazard ratios [HRs] with 95% confidence interval [CIs] for the stratified primary analysis, <italic>p</italic> value versus placebo; 1.32 [0.92, 1.89]; <italic>p</italic>&#x02009;=&#x02009;.10), 5.4 months (1.45 [1.01, 2.06] <italic>p</italic>&#x02009;=&#x02009;.04), and 5.8 months, respectively (Fig. <xref rid="onco12049-fig-0001" ref-type="fig">1</xref>), after a median follow&#x02010;up of 5.1, 3.8, and 5.5 months, respectively. Median OS for the FOLFIRI/simtuzumab 700 mg, FOLFIRI/simtuzumab 200 mg, and FOLFIRI/placebo was 11.4 months (adjusted HR, [95% CIs] for the stratified OS primary analysis, <italic>p</italic> value versus placebo; 1.23 [0.80, 1.91]; <italic>p</italic>&#x02009;=&#x02009;.25), 10.5 months (1.50 [0.98, 2.30]; <italic>p</italic>&#x02009;=&#x02009;.06), and 16.3 months, respectively (Fig. <xref rid="onco12049-fig-0002" ref-type="fig">2</xref>). The adjusted HRs for PFS and OS for the simtuzumab arms compared with placebo were all greater than 1. The ORRs in FOLFIRI/simtuzumab 700 mg, FOLFIRI/simtuzumab 200 mg, and FOLFIRI/placebo were 11.9%, 5.9%, and 10.0%, respectively. The difference (95% CI) in ORR for patients treated with 700 mg FOLFIRI plus simtuzumab versus patients treated with FOLFIRI plus placebo was 2.0% (&#x02212;8.1, 11.9; <italic>p</italic>&#x02009;=&#x02009;.69) and &#x02212;4.1% (&#x02212;13.3, 4.6; <italic>p</italic>&#x02009;=&#x02009;.33) for patients treated with 200 mg FOLFIRI plus simtuzumab compared with FOLFIRI plus placebo. Results from sensitivity analyses were consistent with the primary analyses.</p><p>The safety profile in the patient groups who received FOLFIRI combined with simtuzumab was not different from patients who received FOLFIRI with placebo. The most common adverse events (AEs) deemed by the investigator to be related to study treatment were fatigue, diarrhea, nausea and neutropenia. AEs greater than or equal to grade 3 were reported in 59.5% in the FOLFIRI/simtuzumab 700 mg group, 67.1% in the FOLFIRI/simtuzumab 200 mg group, and 61.3% in the FOLFIRI/placebo group. Seven AEs leading to death occurred during this study; one case of febrile neutropenia was deemed related to FOLFIRI treatment. None of the deaths on study were considered related to simtuzumab.</p><p>In conclusion, the addition of simtuzumab to FOLFIRI did not improve PFS, OS, or ORR in patients with metastatic <italic>KRAS</italic> mutant CRC.</p></sec><sec id="onco12049-sec-1212"><title>Figures and Tables</title><fig fig-type="Figure" xml:lang="en" id="onco12049-fig-0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Stratified Kaplan&#x02013;Meier plot of progression&#x02010;free survival by investigator assessment (FAS population).</p><p>Abbreviations: CI, confidence interval; FAS, full analysis set (all patients randomized and treated with &#x02265;1 dose of study drug); HR, hazard ratio (numbers in brackets are 95% CIs); PFS, progression&#x02010;free survival; SIM, simtuzumab.</p></caption><graphic id="nlm-graphic-9" specific-use="sourcefile-name" xlink:href="onco12049-fig-0001"><alt-text>image</alt-text></graphic></fig><fig fig-type="Figure" xml:lang="en" id="onco12049-fig-0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Stratified Kaplan&#x02013;Meier plot of overall survival (FAS population).</p><p>Abbreviations: CI, confidence interval; FAS, full analysis set (all patients randomized and treated with &#x02265;1 dose of study drug); HR, hazard ratio (numbers in brackets are 95% CIs); OS, overall survival; SIM, simtuzumab.</p></caption><graphic id="nlm-graphic-13" specific-use="sourcefile-name" xlink:href="onco12049-fig-0002"><alt-text>image</alt-text></graphic></fig><table-wrap id="onco12049-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1.</label><caption><title>The efficacy endpoints (FAS analysis set)</title></caption><graphic id="nlm-graphic-17" specific-use="sourcefile-name" xlink:href="onco12049-tbl-0001"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12049-note-0006"><label>a</label><p>Stratified primary analysis per investigator assessment. The results per Independent Review Committee were similar to those obtained by investigator assessment.</p></fn><fn id="onco12049-note-0007"><label>b</label><p><italic>p</italic> values based on stratified two&#x02010;sided log&#x02010;rank test.</p></fn><fn id="onco12049-note-0008"><label>c</label><p><italic>p</italic> values based on Cochran&#x02013;Mantel&#x02013;Haenszel test adjusted for stratification factors.</p></fn><fn id="onco12049-note-0009"><p>Abbreviations: CI, confidence interval; CR, complete response; FAS, full analysis set (all patients randomized and treated with &#x02265;1 dose of study drug); HR, hazard ratio; KM, Kaplan&#x02013;Meier; ORR, objective response rate; OS, overall survival; PFS, progression&#x02010;free survival; PR, partial response.</p></fn></table-wrap-foot></table-wrap><table-wrap id="onco12049-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Demographic and baseline characteristics (FAS analysis set)</title></caption><graphic id="nlm-graphic-19" specific-use="sourcefile-name" xlink:href="onco12049-tbl-0013"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12049-note-0016"><p>Abbreviations: CEA, carcinoembryonic antigen; FAS, full analysis set (all patients randomized and treated with &#x02265;1 dose of study drug); IRR, Independent Radiology Review; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="onco12049-sec-6212"><p><boxed-text position="anchor" orientation="portrait"><p><ext-link ext-link-type="uri" xlink:href="http://clinicaltrialresults.theoncologist.com/search/results">Click here to access other published clinical trials</ext-link>.</p></boxed-text></p></sec></body><back><ack id="onco12049-sec-0013"><title>Acknowledgments</title><p>Medical writing and editorial support was provided by Ewa Wandzioch Ph.D., of AlphaBioCom, LLC, King of Prussia, Pennsylvania, and was funded by Gilead Sciences, Inc.</p></ack><fn-group><fn fn-type="other" id="onco12049-note-0201"><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>
<bold>Identifier</bold>: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01479465">NCT01479465</ext-link></p><p><bold>Sponsor(s)</bold>: Gilead Sciences, Inc., Foster City, California, USA</p><p><bold>Principal Investigator</bold>: J. Randolph Hecht</p><p><bold>IRB Approved</bold>: Yes</p></fn></fn-group><sec id="onco12049-sec-0014" sec-type="disclosure"><title>Disclosures</title><p><bold>J. Randolph Hecht:</bold> Amgen, Genentech, Boston Biomedical (C/A), Amgen, Symphogen,Merrimack Pharmaceuticals (RF); <bold>Al B. Benson III:</bold> Genentech/Roche, Sanofi, Bristol&#x02010;Myers Squibb, Merck Serono, Merck/Schering Plough, Spectrum Pharmaceuticals, Lilly/ImClone, Celgene, Genomic Health, Vicus Therapeutics, Pharmacyclics, Precision Therapeutics, Taiho Pharmaceutical, Bayer, Alchemia, Infinity Pharmaceuticals, Boehringer Ingelheim, Astellas Pharma, EMD Serono (C/A), Genentech/Roche, Sanofi, Bristol&#x02010;Myers Squibb, Merck Serono, Merck/Schering Plough, Spectrum Pharmaceuticals, Lilly/ImClone, Celgene, Genomic Health, Vicus Therapeutics, Pharmacyclics, Precision Therapeutics, Taiho Pharmaceutical, Bayer, Alchemia, Infinity Pharmaceuticals, Boehringer Ingelheim, Astellas Pharma, EMD Serono, AVEO, Gilead Sciences (H), Genentech, Gilead Sciences, Amgen, Astellas Pharma, Bayer/Onyx, Novartis, Alchemia, AVEO, Infinity Pharmaceuticals, Merck Serono, EMD Serono (RF); <bold>Yingsi Yang:</bold> Gilead Sciences, Inc. (E). The other authors indicated no financial relationships.</p><p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p></sec><ref-list content-type="cited-references"><title>References</title><ref id="onco12049-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="onco12049-cit-0001">
<string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, 
<string-name><surname>Soerjomataram</surname>
<given-names>I</given-names></string-name>, 
<string-name><surname>Dikshit</surname>
<given-names>R</given-names></string-name> et al. <article-title>Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012</article-title>. <source>Int J Cancer</source>
<year>2015</year>;<volume>136</volume>:<fpage>E359</fpage>&#x02013;<lpage>E386</lpage>.
<pub-id pub-id-type="pmid">25220842</pub-id></mixed-citation></ref><ref id="onco12049-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="onco12049-cit-0002">
<string-name><surname>Armaghany</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Wilson</surname>
<given-names>JD</given-names></string-name>, 
<string-name><surname>Chu</surname>
<given-names>Q</given-names></string-name> et al. <article-title>Genetic alterations in colorectal cancer</article-title>. <source>Gastrointest Cancer Res</source>
<year>2012</year>;<volume>5</volume>:<fpage>19</fpage>&#x02013;<lpage>27</lpage>.
<pub-id pub-id-type="pmid">22574233</pub-id></mixed-citation></ref><ref id="onco12049-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="onco12049-cit-0003">
<string-name><surname>Benvenuti</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Sartore&#x02010;Bianchi</surname>
<given-names>A</given-names></string-name>, 
<string-name>
<surname>Di Nicolantonio</surname>
<given-names>F</given-names></string-name> et al. <article-title>Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti&#x02010;epidermal growth factor receptor antibody therapies</article-title>. <source>Cancer Res</source>
<year>2007</year>;<volume>67</volume>:<fpage>2643</fpage>&#x02013;<lpage>2648</lpage>.
<pub-id pub-id-type="pmid">17363584</pub-id></mixed-citation></ref><ref id="onco12049-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="onco12049-cit-0004">
<string-name><surname>Phipps</surname>
<given-names>AI</given-names></string-name>, 
<string-name><surname>Buchanan</surname>
<given-names>DD</given-names></string-name>, 
<string-name><surname>Makar</surname>
<given-names>KW</given-names></string-name> et al. <article-title>KRAS&#x02010;mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers</article-title>. <source>Br J Cancer</source>
<year>2013</year>;<volume>108</volume>:<fpage>1757</fpage>&#x02013;<lpage>1764</lpage>.
<pub-id pub-id-type="pmid">23511557</pub-id></mixed-citation></ref><ref id="onco12049-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="onco12049-cit-0005">NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. 2016. Available at <ext-link ext-link-type="uri" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf">https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf</ext-link>. Accessed May 12, <year>2016</year>.
</mixed-citation></ref><ref id="onco12049-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="onco12049-cit-0006">
<string-name><surname>Bremnes</surname>
<given-names>RM</given-names></string-name>, 
<string-name><surname>D&#x000f8;nnem</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Al&#x02010;Saad</surname>
<given-names>S</given-names></string-name> et al. <article-title>The role of tumor stroma in cancer progression and prognosis: Emphasis on carcinoma&#x02010;associated fibroblasts and non&#x02010;small cell lung cancer</article-title>. <source>J Thorac Oncol</source>
<year>2011</year>;<volume>6</volume>:<fpage>209</fpage>&#x02013;<lpage>217</lpage>.
<pub-id pub-id-type="pmid">21107292</pub-id></mixed-citation></ref><ref id="onco12049-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="onco12049-cit-0007">
<string-name><surname>Bhowmick</surname>
<given-names>NA</given-names></string-name>, 
<string-name><surname>Neilson</surname>
<given-names>EG</given-names></string-name>, 
<string-name><surname>Moses</surname>
<given-names>HL.</given-names></string-name>
<article-title>Stromal fibroblasts in cancer initiation and progression</article-title>. <source>Nature</source>
<year>2004</year>;<volume>432</volume>:<fpage>332</fpage>&#x02013;<lpage>337</lpage>.
<pub-id pub-id-type="pmid">15549095</pub-id></mixed-citation></ref><ref id="onco12049-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="onco12049-cit-0008">
<string-name><surname>Fong</surname>
<given-names>SF</given-names></string-name>, 
<string-name><surname>Dietzsch</surname>
<given-names>E</given-names></string-name>, 
<string-name><surname>Fong</surname>
<given-names>KS</given-names></string-name> et al. <article-title>Lysyl oxidase&#x02010;like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors</article-title>. <source>Genes Chromosomes Cancer</source>
<year>2007</year>;<volume>46</volume>:<fpage>644</fpage>&#x02013;<lpage>655</lpage>.
<pub-id pub-id-type="pmid">17394133</pub-id></mixed-citation></ref><ref id="onco12049-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="onco12049-cit-0009">
<string-name><surname>Barry&#x02010;Hamilton</surname>
<given-names>V</given-names></string-name>, 
<string-name><surname>Spangler</surname>
<given-names>R</given-names></string-name>, 
<string-name><surname>Marshall</surname>
<given-names>D</given-names></string-name> et al. <article-title>Allosteric inhibition of lysyl oxidase&#x02010;like&#x02010;2 impedes the development of a pathologic microenvironment</article-title>. <source>Nat Med</source>
<year>2010</year>;<volume>16</volume>:<fpage>1009</fpage>&#x02013;<lpage>1017</lpage>.
<pub-id pub-id-type="pmid">20818376</pub-id></mixed-citation></ref><ref id="onco12049-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="onco12049-cit-0010">
<string-name><surname>Zaffryar&#x02010;Eilot</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Marshall</surname>
<given-names>D</given-names></string-name>, 
<string-name><surname>Voloshin</surname>
<given-names>T</given-names></string-name> et al. <article-title>Lysyl oxidase&#x02010;like&#x02010;2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours</article-title>. <source>Carcinogenesis</source>
<year>2013</year>;<volume>34</volume>:<fpage>2370</fpage>&#x02013;<lpage>2379</lpage>.
<pub-id pub-id-type="pmid">23828904</pub-id></mixed-citation></ref><ref id="onco12049-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="onco12049-cit-0011">
<string-name><surname>Payne</surname>
<given-names>SL</given-names></string-name>, 
<string-name><surname>Hendrix</surname>
<given-names>MJ</given-names></string-name>, 
<string-name><surname>Kirschmann</surname>
<given-names>DA.</given-names></string-name>
<article-title>Paradoxical roles for lysyl oxidases in cancer&#x02013;a prospect</article-title>. <source>J Cell Biochem</source>
<year>2007</year>;<volume>101</volume>:<fpage>1338</fpage>&#x02013;<lpage>1354</lpage>.
<pub-id pub-id-type="pmid">17471532</pub-id></mixed-citation></ref><ref id="onco12049-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="onco12049-cit-0012">
<string-name><surname>Hecht</surname>
<given-names>JR</given-names></string-name>, 
<string-name><surname>Bendell</surname>
<given-names>JC</given-names></string-name>, 
<string-name><surname>Vyushkov</surname>
<given-names>D</given-names></string-name> et al. <article-title>A phase II, randomized, double&#x02010;blinded, placebo&#x02010;controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma</article-title>. <source>J Clin Oncol</source>
<year>2015</year>;33:abstr 3537.
</mixed-citation></ref><ref id="onco12049-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="onco12049-cit-0013">
<string-name><surname>Rodriguez</surname>
<given-names>HM</given-names></string-name>, 
<string-name><surname>Vaysberg</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Mikels</surname>
<given-names>A</given-names></string-name> et al. <article-title>Modulation of lysyl oxidase&#x02010;like 2 enzymatic activity by an allosteric antibody inhibitor</article-title>. <source>J Biol Chem</source>
<year>2010</year>;<volume>285</volume>:<fpage>20964</fpage>&#x02013;<lpage>20974</lpage>.
<pub-id pub-id-type="pmid">20439985</pub-id></mixed-citation></ref><ref id="onco12049-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="onco12049-cit-0014">
<string-name>
<surname>Van Bergen</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Marshall</surname>
<given-names>D</given-names></string-name>, 
<string-name>
<surname>Van de Veire</surname>
<given-names>S</given-names></string-name> et al. <article-title>The role of LOX and LOXL2 in scar formation after glaucoma surgery</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<year>2013</year>;<volume>54</volume>:<fpage>5788</fpage>&#x02013;<lpage>5796</lpage>.
<pub-id pub-id-type="pmid">23821193</pub-id></mixed-citation></ref><ref id="onco12049-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="onco12049-cit-0015">
<string-name><surname>Peng</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Ran</surname>
<given-names>YL</given-names></string-name>, 
<string-name><surname>Hu</surname>
<given-names>H</given-names></string-name> et al. <article-title>Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway</article-title>. <source>Carcinogenesis</source>
<year>2009</year>;<volume>30</volume>:<fpage>1660</fpage>&#x02013;<lpage>1669</lpage>.
<pub-id pub-id-type="pmid">19625348</pub-id></mixed-citation></ref><ref id="onco12049-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="onco12049-cit-0016">
<string-name><surname>LoRusso</surname>
<given-names>P</given-names></string-name>, 
<string-name><surname>Hecht</surname>
<given-names>J</given-names></string-name>, 
<string-name><surname>Thai</surname>
<given-names>D</given-names></string-name> et al. <article-title>Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors</article-title>. <source>J Clin Oncol</source>
<year>2014</year>;<volume>32</volume>:abstr 554.
</mixed-citation></ref></ref-list></back></article>